Pulmonary hypertension is a significant clinical entity severely affecting the longevity and quality of life for patients with either primary or secondary' forms of this disorder. Regardless of its underlying cause, pulmonary hypertension remains intractable to traditional pharmacotherapy. Recent basic genetic and preclinical pharmacological] studies suggest that newly developed agents modifying endothelin activity may have a potential role in pulmonary hypertension. Nonetheless, it is highly likely that general principles of pharmacology predictive of issues of non-specificity and adverse effects as well as target alterations leading to tachyphylaxis and desensitization will ultimately limit the use of new generation endothelin modifiers. In the current proposal, we suggest that advances in non-viral based genetic therapy may provide novel alternatives to traditional pharmacotherapy. In particular, delivery of antisense Oligodeoxynucleotides (ODN) to endothelin-1 lET-l) by immunoliposome can be used to down regulate pulmonary' endothelial ET-1 biosynthesis and similar application with RNA/DNA chimeric oligonucleotide may more permanently silence such expression. Accordingly, specific aims of this comprehensive proposal are:
Aim 1 : To develop an oligonucleotide-based approach to achieve efficient down-regulation of ET-1 in endothelial cells. ODN scanning arrays and ET-1 ELISA will be employed to identity - antisense ODNs that are highly efficient in inhibiting the ET-1 expression in mouse lung endothelial cells. In addition, RNA/DNA chimeric oligonucleotides will be investigated as an approach to achieve a long-term silencing of ET-1 in pulmonary endothelium.
Aim 2 : To develop novel delivery, systems to achieve efficient delivery of oligonucleotide to pulmonary endothelium with reduced toxicity.
Aim 3 : To investigate the biological effect of tissue-specific down-regulation of ET-1 in normal mice and in mice with PHT. The current proposal will lead to a better understanding of the roles of ET-1 in mouse hypoxia-induced pulmonary hypertension and provide experimental and preclinical support for rational pharmacogenetic approach to pulmonary hypertensive disorders. Down regulation of ET-1 biosynthesis by pulmonary endothelium by immunoliposome-mediated delivery of ODN may by itself, or in combination with"""""""" direct pulmonary vasorelaxants (e.g. nitric oxide and oxygen), provide an approach to prevent the progressive pathological aspects of PHT and ameliorate return towards more normal pulmonary vascular structure and function.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL068688-04
Application #
7094081
Study Section
Special Emphasis Panel (ZRG1-SSS-3 (03))
Program Officer
Denholm, Elizabeth M
Project Start
2003-08-01
Project End
2008-07-31
Budget Start
2006-08-01
Budget End
2008-07-31
Support Year
4
Fiscal Year
2006
Total Cost
$358,613
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Li, Jiang; Zhang, Yifei; Kuruba, Ramalinga et al. (2011) Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol 80:191-200
Gao, Xiang; Kuruba, Ramalinga; Damodaran, Krishnan et al. (2009) Polyhydroxylalkyleneamines: a class of hydrophilic cationic polymer-based gene transfer agents. J Control Release 137:38-45
Kuruba, Ramalinga; Wilson, Annette; Gao, Xiang et al. (2009) Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation. AAPS J 11:23-30
Li, Jiang; Wilson, Annette; Gao, Xiang et al. (2009) Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J Pharmacol Exp Ther 331:234-43
He, Fengtian; Zhang, Qiuhong; Kuruba, Ramalinga et al. (2008) Upregulation of decorin by FXR in vascular smooth muscle cells. Biochem Biophys Res Commun 372:746-51
Li, Jiang; Wilson, Annette; Kuruba, Ramalinga et al. (2008) FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 77:169-77
Straub, Adam C; Clark, Katherine A; Ross, Mark A et al. (2008) Arsenic-stimulated liver sinusoidal capillarization in mice requires NADPH oxidase-generated superoxide. J Clin Invest 118:3980-9
Zhang, Qiuhong; He, Fengtian; Kuruba, Ramalinga et al. (2008) FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc Res 77:560-9
He, Fengtian; Li, Jiang; Mu, Ying et al. (2006) Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98:192-9
Wilson, Annette; He, Fengtian; Li, Jiang et al. (2005) Targeted delivery of therapeutic oligonucleotides to pulmonary circulation. Adv Genet 54:21-41

Showing the most recent 10 out of 12 publications